1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Regulation

Bacterial Outbreaks Triggering Tougher FDA Reprocessing Standards

Inadequate validation testing paired with highly-publicized bacterial outbreaks in Illinois and California involving use of contaminated duodenoscopes has led to stricter reprocessing standards for those devices. And FDA is likely moving towards tougher reprocessing requirements more broadly for reusable devices in an upcoming guidance.

Prior to recent bacterial outbreaks at hospitals involving lingering carbapenem-resistant (CRE) bacteria on duodenoscopes, FDA was only requiring statements from endoscope manufacturers that they have validated their reprocessing instructions for disinfecting the reusable scopes. But now, after seeing some inadequate cleanliness test results from the companies – “we are asking to see a higher safety margin," FDA told “The Gray Sheet” March 5.

“Given the complexity of these devices, and our knowledge that failure to follow the cleaning instructions is the most common...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

Under Pressure: How To Safeguard The EU Responsible Person

 
• By Amanda Maxwell

The roles and responsibilities of EU medtech’s persons responsible for regulatory compliance vary widely in role and risk exposure. The recent TEAM-PRRC meeting highlighted how vulnerable they can be and the steps to protect themselves.

Number of Persons Responsible For Regulatory Compliance Grows Nearly 10%

 
• By Amanda Maxwell

The EU’s Medical Device and IVD Regulations require every manufacturer and authorized representative to have a PRRC. As compliance becomes mandatory for increasing numbers of manufacturers, figures are soaring and this role is becoming both increasingly distinctive and more complex.

Italy’s Responsible Person Sanctions Approach Raises Eyebrows

 
• By Amanda Maxwell

Fines are a fact of life when it comes to manufacturers’ compliance with EU rules on persons responsible for regulatory compliance. But Italy’s stance adds pressure on individuals appointed to the role.

A Trillion On The Table. Addressing Disparities In Women’s Health Isn’t Just Right. It’s Smart.

 
• By Brian Bossetta

Advocates spanning the spectrum of women’s health met in Manhattan to discuss the gender disparities that remain in healthcare and how public policy can correct them and the enormous ROI investors in women’s health can potentially reap.

More from Policy & Regulation

Smaller Companies Next Frontier for FDA’s Voluntary Improvement Program

 
• By Elizabeth Orr

At the Medical Device Innovation Consortium summit, Cogmedix's Scott Cook discussed the challenges and benefits of transitioning to the FDA's Voluntary Improvement Program, which promotes honesty and opportunities for improvement, leading to faster market access and cost savings.

Italy’s Responsible Person Sanctions Approach Raises Eyebrows

 
• By Amanda Maxwell

Fines are a fact of life when it comes to manufacturers’ compliance with EU rules on persons responsible for regulatory compliance. But Italy’s stance adds pressure on individuals appointed to the role.

A Trillion On The Table. Addressing Disparities In Women’s Health Isn’t Just Right. It’s Smart.

 
• By Brian Bossetta

Advocates spanning the spectrum of women’s health met in Manhattan to discuss the gender disparities that remain in healthcare and how public policy can correct them and the enormous ROI investors in women’s health can potentially reap.